XERS Quote, Financials, Valuation and Earnings

AnaptysBio has a net margin of -15.34% compared to Xeris Biopharma Holdings's net margin of -141.62%. Xeris Biopharma Holdings's return on equity of -1019.2% beat AnaptysBio's return on equity of -284.76%.

Xeris Biopharma Holdings has a consensus price target of $6.10, signalling upside risk potential of 20.46%. On the other hand AnaptysBio has an analysts' consensus of $42.55 which suggests that it could grow by 59.47%. Given that AnaptysBio has higher upside potential than Xeris Biopharma Holdings, analysts believe AnaptysBio is more attractive than Xeris Biopharma Holdings.

Xeris Biopharma Holdings has a beta of 0.700, which suggesting that the stock is 29.996% less volatile than S&P 500. In comparison AnaptysBio has a beta of -0.274, suggesting its less volatile than the S&P 500 by 127.4%.

Xeris Biopharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AnaptysBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings pays -- of its earnings as a dividend. AnaptysBio pays out -- of its earnings as a dividend.

Xeris Biopharma Holdings quarterly revenues are $60.1M, which are larger than AnaptysBio quarterly revenues of $27.8M. Xeris Biopharma Holdings's net income of -$9.2M is higher than AnaptysBio's net income of -$39.3M. Notably, Xeris Biopharma Holdings's price-to-earnings ratio is -- while AnaptysBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings is 3.52x versus 7.00x for AnaptysBio. Usually stocks with elevated PS ratios are considered overvalued.

Design Therapeutics has a net margin of -15.34% compared to Xeris Biopharma Holdings's net margin of --. Xeris Biopharma Holdings's return on equity of -1019.2% beat Design Therapeutics's return on equity of --.

Xeris Biopharma Holdings has a consensus price target of $6.10, signalling upside risk potential of 20.46%. On the other hand Design Therapeutics has an analysts' consensus of $7.33 which suggests that it could grow by 82.42%. Given that Design Therapeutics has higher upside potential than Xeris Biopharma Holdings, analysts believe Design Therapeutics is more attractive than Xeris Biopharma Holdings.

Xeris Biopharma Holdings has a beta of 0.700, which suggesting that the stock is 29.996% less volatile than S&P 500. In comparison Design Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Xeris Biopharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Design Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings pays -- of its earnings as a dividend. Design Therapeutics pays out -- of its earnings as a dividend.

Xeris Biopharma Holdings quarterly revenues are $60.1M, which are larger than Design Therapeutics quarterly revenues of --. Xeris Biopharma Holdings's net income of -$9.2M is higher than Design Therapeutics's net income of -$17.7M. Notably, Xeris Biopharma Holdings's price-to-earnings ratio is -- while Design Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings is 3.52x versus -- for Design Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -15.34% compared to Xeris Biopharma Holdings's net margin of -49.65%. Xeris Biopharma Holdings's return on equity of -1019.2% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Xeris Biopharma Holdings has a consensus price target of $6.10, signalling upside risk potential of 20.46%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 30.77%. Given that NovaBay Pharmaceuticals has higher upside potential than Xeris Biopharma Holdings, analysts believe NovaBay Pharmaceuticals is more attractive than Xeris Biopharma Holdings.

Xeris Biopharma Holdings has a beta of 0.700, which suggesting that the stock is 29.996% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Xeris Biopharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Xeris Biopharma Holdings quarterly revenues are $60.1M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Xeris Biopharma Holdings's net income of -$9.2M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Xeris Biopharma Holdings's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings is 3.52x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Zevra Therapeutics has a net margin of -15.34% compared to Xeris Biopharma Holdings's net margin of -15.19%. Xeris Biopharma Holdings's return on equity of -1019.2% beat Zevra Therapeutics's return on equity of -198.46%.

Xeris Biopharma Holdings has a consensus price target of $6.10, signalling upside risk potential of 20.46%. On the other hand Zevra Therapeutics has an analysts' consensus of $22.75 which suggests that it could grow by 79.7%. Given that Zevra Therapeutics has higher upside potential than Xeris Biopharma Holdings, analysts believe Zevra Therapeutics is more attractive than Xeris Biopharma Holdings.

Xeris Biopharma Holdings has a beta of 0.700, which suggesting that the stock is 29.996% less volatile than S&P 500. In comparison Zevra Therapeutics has a beta of 1.965, suggesting its more volatile than the S&P 500 by 96.525%.

Xeris Biopharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zevra Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings pays -- of its earnings as a dividend. Zevra Therapeutics pays out -- of its earnings as a dividend.

Xeris Biopharma Holdings quarterly revenues are $60.1M, which are larger than Zevra Therapeutics quarterly revenues of $20.4M. Xeris Biopharma Holdings's net income of -$9.2M is lower than Zevra Therapeutics's net income of -$3.1M. Notably, Xeris Biopharma Holdings's price-to-earnings ratio is -- while Zevra Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings is 3.52x versus 15.38x for Zevra Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.